Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy)

NCT03682770 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

148

Enrollment

INDUSTRY

Sponsor class

Conditions

Peanut Allergy

Interventions

DRUG: Dupilumab
DRUG: Placebo matching dupilumab
DRUG: AR101

Sponsor

Regeneron Pharmaceuticals

Collaborators

[object Object]
[object Object]